Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2024-04-25 Proxy Solicitation & In…
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
REGENERON PHARMACEUTICALS, INC. - DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC for Regeneron Pharmaceuticals, Inc. It is titled 'PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934' and relates to the 2024 Annual Meeting. The content includes voting items such as election of directors, ratification of auditors, and advisory vote on executive compensation. This type of document is used to solicit shareholder votes and provide information about matters to be voted on at the annual meeting. It is not the annual report itself, nor an earnings release or other financial report. The document matches the description of Proxy Solicitation & Information Statement (PSI). The document length is 3814 characters, which is typical for a proxy statement and not a brief announcement or a full annual report. Therefore, the correct classification is PSI.
2024-04-25 English
REGENERON PHARMACEUTICALS, INC. - DEF 14A
Proxy Solicitation & Information Statement
2024-04-25 English
ARS Filing
Annual Report
2024-04-25 English
PRIMARY DOCUMENT
Director's Dealing
2024-04-03 English
4 Filing
Director's Dealing
2024-04-03 English
Regulatory Filings 2024
Regulatory Filings
2024-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.